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Abstract
Backgound: The formation of bony spurs and ankylosis is a key pathognomic feature in ankylosing spondylitis (AS)
and results in functional impairment. The aim of this study was to investigate the role of IL-32γ in osteoblast (OB)
differentiation and its association with the pathogenesis of AS.
Methods: The concentration and expression of IL-32γ were evaluated in synovial fluid and tissue from patients with AS,
rheumatoid arthritis (RA) and osteoarthritis (OA), using enzyme-linked immunosorbent assay and immunohistochemistry.
To establish whether IL-32γ affects OB differentiation, we used calvarial cells of IL-32γ transgenic (TG) mice or wild-type
(WT) mice. To elucidate the mechanism of osteoblastogenesis, levels of regulators were assayed in IL-32γ TG mice and in
primary OBs after IL-32γ stimulation.
Results: The IL-32γ levels were higher in the synovial fluid of AS patients compared with RA or OA patients and the
expression of IL-32 was higher in AS synovia than in RA or OA synovia. Additional IL-32γ stimulation in precursor cells
enhanced OB differentiation potentially and IL-32γ TG mice showed higher rates of OB differentiation than WT
mice. IL-32γ reduced the expression of DKK-1, a negative regulator, in both WT precursor cells and human OBs
and the constitutive expression of DKK-1 was suppressed in calvarial cells from IL-32γ TG mice.
Conclusions: The elevated level of IL-32γ in AS joint could enhance OB differentiation via DKK-1 suppression.
Therefore, IL-32γ might be a putative molecular target to prevent the abnormal bone formation in AS.
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Backgound
Ankylosing spondylitis (AS) is a chronic inflammatory
form of arthritis that primarily affects the spine. The for-
mation of bony spurs and ankylosis, which cause func-
tional impairment in AS patients, are the characteristic
axial findings of AS. Besides the axial skeleton, peripheral
joints are also involved in about 30–50 % of primary AS
during the disease course, which is usually follows an
asymmetric and oligoarticular pattern [1, 2]. Interestingly,
new bone formation at entheseal sites of the peripheral
joint was commonly seen in AS [3].
The new bone formation in AS might be related to ac-
tive repair following the damage caused by inflammation
[4, 5]; that is, inflammation and bone formation appear
to occur at different times, with the former preceding
the latter. However, direct bone damage does not seem
to be essential, given that inhibition of the activity of the
osteoclasts did not prevent bone formation in animal ex-
periments [6]. Therefore, the mechanism that underlies
the proliferative bone formation in AS remain uncertain.
Bone formation requires the differentiation and activa-
tion of osteoblasts (OBs), which synthesize the bone matrix
and originate from mesenchymal stem cells. The differenti-
ation and activation of OBs are regulated by various mole-
cules. Of these, parathyroid hormone, bone morphogenetic
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protein (BMP), and members of the Wnt protein family
are the most prominent factors. Wnt proteins activate
at least three distinct pathways: the canonical (β-catenin-
dependent), calcium-dependent, and planar polarity path-
ways [7]. Of these, the canonical pathway is best understood.
Briefly, when Wnt molecules bind to Frizzled and Lrp5/6 on
the surface of osteoprogenitors, stabilized β-catenin translo-
cates into the nucleus and enhances the transcription of
genes related to OB formation [8]. Dickkopf-1 (DKK-1) is a
product of OBs that is a potent Wnt pathway inhibitor and
inhibits proper differentiation of OBs. Mice that overexpress
DKK-1 in OBs develop osteopenia because of reduced OB
abundance and decreased bone formation [9]. Blocking
DKK-1 transforms the bone-destruction pattern to a
bone-creation pattern in a mouse model [10].
Interleukin (IL)-32, which exhibits the properties of a
proinflammatory cytokine, is produced by T lymphocytes,
natural killer cells, epithelial cells, blood monocytes and
fibroblast-like synoviocytes in the joints and affects
various inflammatory cascades [11–13]. Previously, we
reported that IL-32γ, the biologically active isoform of
IL-32, is a potent mediator of osteoclast differentiation
[14, 15]. However, the biologic function of IL-32γ on
OBs, the other side of bone balance, has never been
investigated.
We report here that IL-32γ accumulates in the joint
fluid and is expressed in the synovia of AS patients at
much higher levels than in the synovia of rheumatoid
arthritis (RA) patients. We first investigated the potentially
pathogenic role of IL-32γ in AS, focusing on OB differen-
tiation using IL-32γ transgenic (TG) mice.
Methods
Sample collection and enzyme-linked immunosorbent
assay
All biologic samples from patients were obtained in ac-
cordance with the approval of the Asan Medical Center
Institutional Review Board (S2013-0986-0003). Informed
consent was obtained from all patients. Peripheral synovial
tissues (from patients who underwent synovectomy), soft
tissues from the axial skeleton (from patients who per-
formed laminectomy) and knee joint fluids were collected
at the Asan Medical Center and Hanyang University
Hospital. Diagnoses either met the modified New York
criteria for AS [16], the 1987 revised criteria for RA
[17], or criteria for osteoarthritis (OA) [18]. Clinical infor-
mation at the time of arthrocentesis was extracted from
an electronic clinical database. The concentrations of
IL-32γ and tumor necrosis factor (TNF)-α were measured
using commercially available kits obtained from YbdY
(Seoul, South Korea) and R&D Systems (Minneapolis,
MN, USA). A commercial enzyme-linked immunosorbent
assay (ELISA) kit (R&D Systems) was also used to
determine the murine DKK-1 proteins secreted in cul-
ture media.
Immunohistochemistry assay
Sections of paraffin-embedded synovial tissue samples
from OA, RA, and AS patients were stained with anti-
IL-32 antibody (Millipore, Billerica, MA, USA) or normal
rabbit IgG (Santa Cruz Biotechnology, Dallas, TX, USA)
according to manufacturer's instructions. Tissue sections
(5 μm thick) were baked at 65 °C for 30 min, and the par-
affin was removed by two washes (5 min each) with xy-
lene. The sections were rehydrated by passage through a
graded series of ethanol solutions (100 % to 70 % ethanol)
and, for antigen retrieval, slides were dipped in citrate
buffer (pH 6.0) and incubated at 95 °C for 5 min. For
permeabilization, the samples were incubated for 10 min
in phosphate-buffered saline (PBS) that contained 0.25 %
Triton X-100 (PBST), and were washed twice with PBS,
with each wash lasting 5 min. To block nonspecific bind-
ing of the antibodies, the samples were incubated with
1 % bovine serum albumin (BSA) in PBST for 1 h and
washed twice with PBST, with each wash lasting 5 min.
To eliminate endogenous peroxidase activity, the tissue
sections were incubated with 3 % H2O2 in PBS for
30 min and washed twice with PBST, with each wash
lasting 5 min. The sections were incubated with anti-
IL-32 (1:100 in PBST) or normal rabbit IgG (1:100 in
PBST) for 30 min at room temperature, and then washed
twice with PBST (with each wash lasting 5 min). There-
after, the samples were incubated for 30 min at room
temperature with anti-mouse or anti-rabbit secondary
antibodies that were conjugated to polymeric horseradish
peroxidase (Dako, Glostrup, Denmark). For colorimetric
detection of the enzymatic reactions, the sections were
incubated with Dako liquid DAB+ substrate chromogen
solution (Dako) for 30 min, before two washes (5 min
each) with PBS. The samples were counterstained with
hematoxylin (Sigma, St Louis, MO, USA) for 1 min, and
then washed twice with distilled water (each wash for
5 min). To stain the nuclei blue, the slides were dipped
once in 0.3 % ammonia in water.
Animals
IL-32γ TG and wild-type (WT) C57BL/6 mice were ob-
tained from Dr. Kim’s laboratory (Konkuk University,
Korea) and SLC, Inc. (Japan), respectively. All experiments
using mice were performed in accordance with the rele-
vant guidelines and regulations on the use of animals at
the Asan Biomedical Research Institute of the Asan
Medical Center (Korea) and were approved by the Institu-
tional Animal Care and Use Committee of the Asan Bio-
medical Research Institute of the Asan Medical Center
(2013-02008).
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Osteoblast differentiation
OB differentiation was performed by isolating primary
mouse OB precursor cells from the calvariae of 1-day-old
mice in accordance with a published protocol [19]. Osteo-
blastic precursor cells of WT and IL-32γ TG mice were
isolated from calvaries by six routine sequential digestions
with 0.1 % collagenase (Gibco BRL, Gaithersburg, MD,
USA) and 0.2 % dispase (Roche, Penzberg, Germany). To
induce OB differentiation, these cells were seeded onto
48-well culture plates at a density of 2 × 104 cells/well and
cultured in osteogenic medium (α-MEM, 10 % fetal bo-
vine serum (FBS), 10 mM β-glycerophosphate, and
50 mg/ml ascorbic acid) for 1 to 4 weeks. The medium
was changed every 3 days. OB differentiation and
mineralization were assessed by detecting alkaline phos-
phatase (ALP) activity or by staining with Alizarin Red
(AR) or Von Kossa (VK) stain.
Human OBs were purchased from Promo Cell (Heidelberg,
Germany). Cells were cultured in OB growth medium
(C-27001) containing fetal calf serum and 100 U/ml of
the penicillin-streptomycin at 37 °C in a humidified at-
mosphere under 5 % (v/v) CO2. Human OBs were treated
with IL-32γ (50 or 100 ng/mL) for 8 h.
Reverse transcription-polymerase chain reaction analysis
Total RNA was isolated from the cells using QIAzol
Lysis reagent (Qiagen, Valencia, CA, USA) and 2 μg was
reverse-transcribed using SuperScript II reverse transcript-
ase (Life Technologies, Carlsbad, CA, USA) according to
manufacturer's instructions. The cDNA generated was
amplified by polymerase chain reaction (PCR) using the
primers shown in Table 1. The PCR conditions were as
follows: denaturation at 94 °C for 30 s, followed by an-
nealing at 55–60 °C for 30 s, and extension at 72 °C for
1 min. The number of cycles fell within the range asso-
ciated with linear amplification (28–34 cycles; GAPDH
required 23 cycles).
Western blotting analysis
WT calvarial OB precursor cells were stimulated with
IL-32 (100 ng/ml) and wnt3a (20 ng/ml) in osteogenic
media. At the indicated times, the cells were washed
with ice-cold PBS and lysed in modified RIPA buffer
(50 mM Tris/HCl (pH 7.4), 1 % Nonidet P40, 0.25 % so-
dium deoxycholate, and 150 mM NaCl) containing pro-
tease and phosphatase inhibitors. Cell lysates were
centrifuged at 10,000 g for 15 min, the supernatants
were collected, and the proteins resolved in 10 % SDS-
PAGE gels. Separated proteins were transferred to a poly-
vinylidene difluoride membrane (Bio-Rad, Hercules, CA
USA), and then blocked for 1 h with 5 % BAS (MP
biomedicals, Auckland, New Zealand) solution in Tris-
buffered saline solution containing 0.1 % Tween 20. The
membrane was then incubated overnight at 4 °C with
antibodies specific for active β-catenin (Non-phospho,
Ser33/37/Thr41, Cell Signaling), total β-catenin, and β-
actin, washed, and incubated for 1 h at room temperature
with the horseradish peroxidase-conjugated secondary
antibody. Reactive proteins were visualized using a
chemiluminescence system (Merck-Millipore, Darmatadt,
Germany).
Statistical analysis
The differences between two groups were calculated using
the Mann-Whitney U-test or an unpaired Student’s t-test,
and the differences among three groups were analyzed by
one-way analysis of variance. The relationships among pa-
rameters were tested by using Spearman’s rank correlation
coefficient. Statistical analyses were considered significant
for p values < 0.05.
Results
IL-32 in the synovial fluids and tissues
To evaluate the involvement of IL-32 in AS pathogenesis,
we first determined the levels of IL-32γ and TNF-α in the
joint fluids from patients with AS, RA, and OA. As shown
in Fig. 1a, the levels of IL-32γ were significantly higher in
AS patients than in either RA or OA patients (p < 0.01).
The levels of TNF-α in the joint fluids from patients with
AS or RA were higher than those from patients with OA.
However, there was no difference in the TNF-α level be-
tween patients with AS and those with RA (Fig. 1b).
Table 2 summarizes the baseline characteristics of the
AS patients (n = 15) and RA patients (n = 17) who under-
went arthrocentesis. In the AS patients, none of the clin-
ical parameters, including age, sex, levels of inflammatory
Table 1 List of primers used for the detection of DKK-1, BMP-2,
BMPRII and LRP-5
Target Sequences
Mouse DKK-1 Forward 5’-GAG GGG AAA TTG AGG AAA GC-3’
Reverse 5’-GCA GGT GTG GAG CCT AGA AG-3’
Mouse BMP-2, Forward 5’-GGG ACC CGC TGT CTT CTA GT-3’
Reverse 5’-TCA ACT CAA ATT CGC TGA GGA C-3’
Mouse BMPRII Forward 5’-TTG GGA TAG GTG AGA GTC GAA T-3’
Reverse 5’-TGT TTC ACA AGA TTG ATG TCC CC-3’
Mouse LRP-5 Forward 5’-CAG GTG CTT GTG TGG AGA GA-3’
Reverse 5’-GTC CAT GAC GAA GTC CAG GT-3’
Mouse GAPDH Forward 5’-AGC CAC ATC GCTCAG ACA-3’
Reverse 5’-GCC CAA TAC GAC CAAATC C-3’
Human DKK-1 Forward 5’-CAT CAG ACT GTG CCT CAG GA-3’
Reverse 5’-CCA CAG TAA CAA CGC TGG AA-3’
Human GAPDH Forward 5’-CGT CTT CAC CAC CAT GGA GA-3’
Reverse 5’-CGG CCA TCA CGC CAC AGT TT-3’
BMP bone morphogenetic protein, BMPRII bone morphogenetic protein receptor II,
DKK-1 Dickkopf-1, LRP-5 low-density lipoprotein receptor-related protein 5
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markers, grade of sacroiliitis, eye involvement, HLA B27
allele, Bath Ankylosing Spondylitis Disease Activity Index
score [20], and modified Stoke Ankylosing Spondylitis
Spine Score (mSASSS) [21], was found to be associated
with the IL-32γ levels in the peripheral joint fluids
(Table 2). Considering mismatch between mSASSS and
IL-32 levels of peripheral joint fluid, peripheral arthritis
could not reflect the severity of the axial joint directly.
We next performed immunohistochemical (IHC) stain-
ing to investigate the levels of IL-32 protein in the joint
tissues from patients with AS, RA, and OA. The IHC
analysis revealed that the IL-32 level was higher in AS
synovial tissues than in RA or OA synovial tissues (Fig. 2a).
The stained cells in the synovial tissue possess spindle-
shaped morphology and these are mostly consistent with
synovial fibroblasts. Further, as shown in Fig. 2b, high
IL-32 level was also detected in axial skeletons around
the facet joint of AS patients compared to those of OA
patients.
Osteoblast differentiation by IL-32γ is accompanied by
the suppression of DKK-1 expression
To understand the direct role of IL-32γ during OB dif-
ferentiation, calvarial cells of WT mice were treated with
IL-32γ (100 ng/ml) in osteogenic media, and changes in
ALP activity, calcium deposition (determined by AR
staining), and mineral deposition (determined by VK
staining) were monitored for 4 weeks. As shown in
Fig. 3a, exposure to exogenous IL-32γ promoted rapid
and marked OB differentiation and matrix maturation,
as indicated by increased ALP activity and increased
numbers of AR- and VK-positive cells. Moreover, re-
gions positive for AR staining were observed only after
2 weeks of IL-32γ treatment. These results clearly sup-
port a role for IL-32γ in promoting OB differentiation.
We next investigated possible regulators that are re-
lated to the IL-32γ pathway at the mRNA level. The
results revealed the IL-32γ induced suppression of
DKK-1, a specific inhibitor of Wnt/β-catenin signaling
that is secreted by OBs. Specifically, the mRNA levels
of this protein were dramatically lower in the calvarial
cells (Fig. 3b), and there was a decrease in the DKK-1
Fig. 1 IL-32 in the synovial fluids of ankylosing spondylitis patients. a IL-32γ levels in joint fluid and b TNF-α levels in joint fluid. Levels of human
IL-32γ and TNF-α in the joint fluid of patients with AS (n = 15), RA (n = 17), and OA (n = 13) were measured using a commercially available ELISA
kit. The bars show the means ± SD; **p < 0.01. AS ankylosing spondylitis, IL interleukin, NS not significant, OA osteoarthritis, RA rheumatoid arthritis,
TNF tumor necrosis factor
Table 2 Baseline characteristics of patients with ankylosing
spondylitis and rheumatoid arthritis
AS (n = 15) RA (n = 17) p-value
Age (years, mean ± SD) 32.9 ± 9.6 56.2 ± 10.4 <0.0001
Sex (male, n (%)) 12 (80.0 %) 2 (11.8 %) <0.0001
ESR (mm/h, mean ± SD) 53.7 ± 35.5 56.5 ± 31.3 NS
CRP (mg/dL, mean ± SD) 3.5 ± 3.5 2.9 ± 3.4 NS
Disease duration (years, mean ± SD) 5.2 ± 6.1 6.1 ± 6.3 NS
Eye involvement (n (%)) 5 (33.3 %) N/A
HLA-B27 positive (n (%)) 13 (86.7 %) N/A
BASDAI (mean ± SD) 4.3 ± 2.3 N/A
mSASSS (mean ± SD) 15.8 ± 16.7 N/A
Sacroiliitis grading (n (%))
Grade 2 3 (20.0 %) N/A
Grade 3 9 (60.0 %) N/A
Grade 4 3 (20.0 %) N/A
Current medications (n (%))
MTX 7 (46.7 %) 14 (82.4 %) 0.062
SSZ 8 (53.3 %) 1 (5.9 %) 0.005
TNFi 3 (20 %) 1 (5.9 %) 0.319
NSAID 13 (86.7 %) 16 (94.1 %) 0.589
AS ankylosing spondylitis, BASDAI bath ankylosing spondylitis disease activity
index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, mSASSS
modified Stoke Ankylosing Spondylitis Spine Score, MTX methotrexate, N/A not
available, NS not significant, NSAID nonsteroidal anti-inflammatory drug, RA
rheumatoid arthritis, SSZ sulfasalazine, TNFi tumor necrosis factor inhibitor
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protein level in culture media after IL-32γ treatment
(Fig. 3c). These results suggested that IL-32γ might
regulate mouse DKK-1 expression. To further validate
the mechanism by which IL-32γ enhances OB differenti-
ation in humans, we also determined the abundances of
DKK-1 mRNAs in human OBs and found the stimulation
with IL-32γ reduced the abundance of DKK-1 mRNAs
(Fig. 3d). To confirm the downstream effects of DKK-1
suppression, the level of active β-catenin was evaluated
after the treatment with IL-32γ or Wnt3a (positive
control). As shown in Fig. 3e, IL-32γ enhanced β-catenin
activation significantly at 48 h, which could be related to
suppression of DKK-1.
Enhanced osteogenic differentiation in IL-32γ transgenic
mice
Given the increased bone volume observed in IL-32γ TG
mice, we next determined the role of OB differentiation
in this phenomenon. The levels of ALP specific activity,
calcium deposition, and mineral deposition indicated higher
rates of osteogenic differentiation in IL-32γ TG mice than
in WT mice (Fig. 4a). Reverse transcription PCR analysis
revealed similar levels of the transcripts of genes that regu-
late OB differentiation—including BMP-2, BMPRII, and
LRP-5—in the calvarial cells of the TG mice and WT mice
after 24 h culture in osteogenic media. Interestingly, simi-
larly to the endogenous reduction in DKK-1 expression in
the OB precursor cells induced by IL-32γ stimulation, the
induction of DKK-1 was dramatically lower in the calvarial
cells from IL-32γ TG mice than those from WT mice
(Fig. 4b). Furthermore, the DKK-1 protein level in the cul-
ture media from IL-32γ TG mice after 1 week of OB differ-
entiation was also decreased (Fig. 4c). This finding suggests
that the stimulation of osteogenic differentiation in IL-32γ
TG mice might be linked to the reduction in the level of
DKK-1 in the OB precursor cells.
Discussion
The current study showed that the proinflammatory
cytokine IL-32 is accumulated in inflamed joints in pa-
tients with AS more than in those with RA or OA that
were selected as the comparison groups; RA is not a
bone-forming disease but an inflammatory disease, whereas
OA is less inflammatory but is a bone-forming disease. The
IL-32 level in RA joints could be expected to be lower than
that in OA when considering the aspect of bone formation.
However, our findings revealing higher levels of IL-32 in
RA joints than in OA joints are consistent with previous re-
ports [12, 14]. We believe that the inflammatory cytokine
IL-32 in RA joints could be accumulated by persistent
inflammatory stimuli, although it was not enough to
overcome bone loss and erosion. OA is characterized
by osteophyte formation reflecting new bone formation,
which is associated mainly with subchondral bone sclerosis,
together with progressive cartilage damage [22], whereas
new bone formation in AS involves a complicated and
Fig. 2 High IL-32 in the peripheral synovia and the axial skeletons of ankylosing spondylitis. a Representative immunohistochemical (IHC) images
of peripheral synovia of AS, RA, or OA stained with antibodies against IL-32 or isotype controls. Synovitis was found in the tissues acquired from
the patients with clinically active AS (36-year-old female, ankle) and RA (52-year-old female, ankle). b Representative IHC images of axial skeletons
of advanced AS (57-year-old female) and OA (79-year-old female) patients who underwent laminectomy. All IHC images are shown at 200×
magnification (scale bars, 100 μm), and are representative of images from three independent experiments. AS ankylosing spondylitis, IL interleukin,
OA osteoarthritis RA, rheumatoid arthritis
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multifactorial sequence generated from the initiating enthe-
seal inflammation.
Here, we verified the ability of IL-32γ to enhance OB
differentiation and characterized how bone formation in
AS differs from that in RA or OA. Our findings provide
the first evidence, to our knowledge, of the high level of
IL-32γ in AS peripheral and axial tissues and its associ-
ation with abnormal bone formation. However, synovitis
of peripheral joints could be a peripheral manifestation
of disease, and does not correlate with axial joint sever-
ity and radiographic progression per se.
We demonstrated that IL-32γ TG mice had higher
potency of osteogenic differentiation than WT mice and
confirmed the enhanced OB differentiation triggered
by the presence of the IL-32γ protein. An important
aspect of IL-32 biology is that the induction of other
Fig. 3 Effect of exogenous IL-32γ on osteoblast differentiation. a WT calvarial osteoblast (OB) precursor cells were cultured for 4 weeks with osteogenic
medium in the absence (None) or presence of IL-32γ (100 ng/ml) to induce OB differentiation. The cells were fixed once a week and were
used for measurement of alkaline phosphatase (ALP) or for staining with alizarin red (AR) or Von Kossa (VK). b WT calvarial cells were stimulated
with IL-32γ (100 ng/ml) in the presence of osteogenic media (OM) for the indicated time and subjected to reverse transcription PCR analysis
of the expression of genes that encode DKK-1, BMP-2, BMPRII, and LRP-5. c The DKK-1 protein level in the culture supernatant from the cells
after 1 week of OB differentiation in the absence (None) or presence of IL-32γ was determined by ELISA. d The relative expressions of DKK-1
mRNA were evaluated in human OBs treated with IL-32γ (50 and 100 ng/ml). e WT calvarial cells were stimulated with IL-32γ (100 ng/ml) and
Wnt3a (20 ng/ml) in osteogenic media for the indicated times and whole cell lysates obtained from cultured cells were analyzed by western
blotting with antibodies specific for active β-catenin, total β-catenin or β-actin (loading control). The relative protein levels were quantified by
densitometry. Data are expressed as the mean ± SD of triplicate experiments; ***p < 0.001, *p < 0.05, versus 0 h treated with IL-32γ; #p < 0.05,
versus 0 h treated with Wnt3a. BMP bone morphogenetic protein, BMPRII bone morphogenetic protein receptor II, DKK-1 Dickkopf-1, IL interleukin,
LRP-5 low-density lipoprotein receptor-related protein 5, W week
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pro-inflammatory cytokines, including TNF, IL-1, IL-18,
and IL-22, has been suggested in human RA [23], indicat-
ing the possible involvement of pro-inflammatory cyto-
kines in IL-32 function. However, it is intriguing that the
IL-32 TG mice, as well as IL-32 treatment, did not show
any significant increases in the production of those cyto-
kines under osteogenic stimulation conditions (Additional
file 1). Interestingly, we found the reduction of IL-18 in
IL-32γ TG mice and in cultures stimulated with IL-32,
although this may not be significant. Unlike other in-
flammatory cytokines, IL-18 demonstrates positive effects
on OB differentiation by mediating anabolic actions of
parathyroid hormone [24]. In addition, IL-32 expression
was correlated with IL-18 expression in the synovia of ex-
perimental arthritis animals and mucosa of patients with
allergic rhinitis [25, 26]. However, we could not exclude
the possibility that IL-32 and IL-18 regulate each other in
a negative manner in OB differentiation. This assumption
requires further investigation. Nevertheless, based on the
knowledge of the inhibitory effects of pro-inflammatory
cytokines (e.g., TNF, IL-1) on OB differentiation [27, 28],
we can conclude that the osteogenic potential of IL-32 is
unlike the activity of other pro-inflammatory cytokines.
A variety of chronic inflammatory diseases, including
AS and RA, are currently treated by TNF inhibitors, es-
pecially in patients refractory to conventional treatments.
Although TNF inhibitors are effective in controlling dis-
ease activity in AS, 2-year follow-up studies demonstrated
no clear effect of this intervention on the development of
bony ankylosis [29–31]. It was proposed that TNF sup-
presses OB differentiation by promoting DKK-1, which is
a master negative regulator of the Wnt/β-catenin pathway
[10]. Furthermore, a recent study revealed that a TNF in-
hibitor significantly decreased the level of serum DKK-1
in AS patients [32]. The emerging view is that TNF in-
hibits new bone formation during the inflammatory
process, but that TNF inhibitors can restore OB function
despite their anti-inflammatory effects.
However, a long-term observational study by Haroon
et al., in which large numbers of patients were analyzed
over a 5-year follow-up period, reported that after adjust-
ing for the baseline mSASSS the AS patients who were
Fig. 4 Osteogenic differentiation in IL-32γ TG mice. a Calvarial cells isolated from wild-type (WT) or IL-32γ transgenic (TG) mice were cultured in
osteogenic medium (OM). The cells were fixed and used for the measurement of alkaline phosphatase (ALP) activity or for staining with alizarin
red (AR), or Von Kossa (VK) stains to assess the degree of OB differentiation and mineralization at 1, 2, 3, and 4 weeks (W). b WT or IL-32γ TG calvarial
cells were stimulated with osteogenic media for 24 h and subjected to reverse transcription PCR analysis of the expression of regulatory genes needed
for OB differentiation, including those that encode DKK-1, BMP-2, BMPRII, and LRP-5. c The DKK-1 protein level in the culture supernatant from the cells
after 1 week of OB differentiation was determined by ELISA. Representative data from at least three independent experiments are shown; ***p < 0.001.
BMP bone morphogenetic protein, BMPRII bone morphogenetic protein receptor II, DKK-1 Dickkopf-1, IL interleukin, LRP-5 low-density lipoprotein
receptor-related protein 5
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administered TNF inhibitors showed a 50 % reduction in
radiographic progression compared to those who had not
received these agents [33]. To date, whether inflammation
and new bone formation are uncoupled or occur simul-
taneously remains controversial. Therefore, considering
the identified effects of IL-32γ on OBs and inflammation,
treatments that target IL-32γ might prevent the uncoup-
ling of inflammation from bony proliferation.
Although little is known about the mechanisms of
syndesmophyte formation in the joints in AS, this likely
involves regulatory molecules, such as Wnt proteins.
Activation of Wnt signaling by blocking its natural in-
hibitor DKK-1 leads to the new bone formation in per-
ipheral joints [10]. Interestingly, DKK-1 inhibition also
leads to a bilateral erosive change and ankylosis of the
sacroiliac joints in TNF TG mice, which have symptoms
that mimic those of sacroiliitis in humans [34]. Given that
DKK-1 is a key factor for joint remodeling during the in-
flammatory process, the AS phenotype might be related to
certain conditions when DKK-1 has been suppressed or
distorted functionally [35]. In this context, IL-32γ could
be one of the important regulators that controls DKK-1
leading to modulation of the Wnt/β-catenin signal during
the pathogenesis of AS.
Despite our interesting results, the limitations of this
study include that ectopic bone formation in the joints,
which can be affected by OB activation, did not develop
in our TG model spontaneously. Moreover, because of
small sample size the levels of IL-32 in the peripheral
joints were not correlated significantly with several clinical
parameters including mSASSS, which might be obstacles
to link our findings to clinical research. Finally, we could
not exclude the effect of age and gender on the IL-32
production clearly, although there was no association in
our samples.
Conclusions
Effective control of soluble factors that are related to
bone proliferation might minimize disease progression
in AS. Here, we show that AS joints have a higher level
of IL-32γ, and the differentiation of OB precursors from
IL-32γ TG mice into mature OBs might be related to
the suppression of DKK-1 expression. The higher levels
of IL-32γ in the joints and tissues of the AS patients
might induce OB differentiation and then trigger atypical
new bone formation. These data suggest that IL-32γ
might be a molecular target with the potential to prevent
radiographic progression in AS.
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show the means ± SD of triplicate experiments. (TIFF 443 kb)
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